SEC Filing Summary: Form 8-K
Business Context and Reporting Period
Company: Petra Acquisition, Inc. (Registrant) in connection with Revelation Biosciences, Inc. (Target).
Date of Report: December 21, 2021.
Context: This Current Report details the execution of financing agreements to support the proposed business combination (SPAC merger) between Petra and Revelation. Revelation is a pre-clinical biotechnology company. The filing addresses measures to ensure sufficient cash remains in the trust account post-redemption to close the transaction.
Key Financial Metrics and Agreements
This filing does not contain historical financial statements (revenue, profit, or cash flow) for the reporting period. Instead, it outlines specific financial commitments and obligations:
- Backstop Agreements: Backstop Subscribers (including AXA Prime Impact Master Fund and LifeSci Venture Partners) agreed to purchase up to $4.5 million of Petra common stock if redemptions exceed $31.5 million.
- Convertible Note: Revelation secured up to $2.5 million in convertible note financing from AXA to fund its portion of the Backstop Agreements.
- Forward Share Purchase Agreement: Meteora Capital Partners committed to purchase additional shares to hold at least 750,000 shares at closing and not redeem them.
- Share Repurchase Obligation: Petra agreed to repurchase up to 750,000 shares from Meteora one year post-closing at a fixed price of $10.2031 per share.
- Escrow Requirement: Petra must place $7,652,325 into escrow at closing to secure the repurchase obligation to Meteora.
Material Changes and Liquidity Implications
The filing highlights a material change in the capital structure and liquidity profile of the post-combination entity ("New Revelation"):
- Liquidity Constraint: The $7.65 million placed in escrow for the Meteora repurchase obligation will not be available to fund New Revelation's operations post-closing.
- Financing Needs: If the repurchase obligation is triggered, New Revelation will require additional immediate financing, which may be dilutive to existing shareholders.
- Redemption Risk: The Backstop Agreements are contingent on redemptions exceeding $31.5 million, indicating a threshold for significant cash outflow from the trust.
Guidance, Risks, and Management Commentary
Management Commentary: The Petra Board did not review financial projections for Revelation because the company is pre-clinical, and such projections would be speculative. A fairness opinion was obtained from Scalar, LLC.
Risks and Contingencies:
- Financing Uncertainty: No assurance exists that additional financing required to meet the Meteora repurchase obligation will be available on favorable terms or at all.
- Clinical Risks: Risks related to the RVL-CLR01 clinical study, including enrollment delays, adverse safety events, and data replication.
- Transaction Risks: Failure to obtain stockholder approval, inability to maintain Nasdaq listing, and uncertainty regarding cash proceeds remaining in the trust after redemptions.
- Regulatory Risks: Potential impact of FDA/EMA decisions on product candidates (REVTx-99, REVTx-200, etc.).
Investor Verification Checklist
- Verify the final redemption rate to determine if the $4.5 million Backstop Agreement is triggered.
- Confirm the availability of the $7.65 million escrow funds and the impact on New Revelation's working capital.
- Review the definitive proxy statement/prospectus (Form S-4) for detailed terms of the Merger Agreement.
- Assess the status of the RVL-CLR01 clinical trial and enrollment progress.
- Monitor for announcements regarding additional financing required to satisfy the Meteora repurchase obligation.